Free Trial

Roger Song Analyst Performance

Biotech Equity Research at Jefferies Financial Group

Roger Song is a stock analyst at Jefferies Financial Group, covering 16 publicly traded companies across a range of sectors. Over the past year, Roger Song has issued 15 stock ratings, including buy and hold recommendations. While full access to Roger Song's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Roger Song's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
18 Last 4 Years
Buy Recommendations
77.78% 14 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy77.8%14 ratings
Hold22.2%4 ratings
Sell0.0%0 ratings

Out of 18 total stock ratings issued by Roger Song at Jefferies Financial Group, the majority (77.8%) have been Buy recommendations, followed by 22.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
16 companies

Roger Song, an analyst at Jefferies Financial Group, currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies
100.0%

Roger Song of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
11 companies
68.8%
MED - DRUGS
4 companies
25.0%
PHARMACEUTICAL PREPARATIONS
1 company
6.3%

Roger Song's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
8/28/2025Initiated Coverage$1.86$5.00Buy
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
8/28/2025Initiated Coverage$1.92$5.00Buy
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
8/22/2025Boost Price Target$5.33$17.00Buy
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
8/5/2025Downgrade$1.47$1.50Hold
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
7/29/2025Boost Price Target$30.37$54.00Buy
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Lower Price Target$2.92$6.00Buy
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
6/18/2025Downgrade$11.38$11.00Hold
CureVac N.V. stock logo
CVAC
CureVac
6/13/2025Reiterated Rating$5.60$5.00Hold
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/29/2025Boost Price Target$25.88$45.00Buy
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4/11/2025Upgrade$7.49$30.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4/1/2025Initiated Coverage$1.92$6.00Buy
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3/14/2025Initiated Coverage$2.65$7.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3/5/2025Initiated Coverage$175.22$245.00Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2/25/2025Initiated Coverage$10.48$26.00Buy
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1/10/2025Reiterated Rating$2.11$2.00Hold